Evanson Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Evanson Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,050	Closed	-$298K	–	274
2020 Q3	$298K	Hold	9,050	–	–	0.05%	183
2020 Q2	$248K	Sell	9,050 -5,000	-36%	-$164K	0.05%	199
2020 Q1	$421K	Sell	14,050 -920	-6%	-$24.4K	0.1%	122
2019 Q4	$414K	Sell	14,970 -5,755	-28%	-$131K	0.08%	146
2019 Q3	$377K	Hold	20,725	–	–	0.08%	151
2019 Q2	$508K	Hold	20,725	–	–	0.1%	115
2019 Q1	$197K	Hold	20,725	–	–	0.04%	227
2018 Q4	$183K	Hold	20,725	–	–	0.04%	214
2018 Q3	$233K	Hold	20,725	–	–	0.05%	213
2018 Q2	$265K	Hold	20,725	–	–	0.05%	206
2018 Q1	$350K	Buy	20,725 +6,675	+48%	+$101K	0.07%	171
2017 Q4	$112K	Hold	14,050	–	–	0.02%	242
2017 Q3	$109K	Buy	+14,050	New	+$88.9K	0.02%	228

Other funds holding IOVA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Evanson Asset Management's IOVA Position: Q4 2020 in Review

Evanson Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2020, closing a stake of 9,050 shares — an estimated $298K sold.

Evanson Asset Management first reported a position in IOVA in Q3 2017 and held it in 13 quarters. The position peaked at $508K in Q2 2019. 269 funds tracked by Wall St. Rank hold IOVA as of Q4 2020.

Evanson Asset Management reported no remaining Iovance Biotherapeutics position as of Q4 2020 after selling out during the quarter.
Evanson Asset Management sold 9,050 Iovance Biotherapeutics shares in Q4 2020, an estimated $298K.
Evanson Asset Management first reported a position in Iovance Biotherapeutics in Q3 2017 and held it in 13 quarters.
Evanson Asset Management's Iovance Biotherapeutics position peaked at $508K in Q2 2019.
269 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2020.

Based on Evanson Asset Management's 13F filing for Q4 2020, filed 22 Jan 2021.